ERBB2 and breast carcinoma: In fact, the TAILORx trial of the Oncotype DX® assay has shown that patients with breast cancer of the luminal subtype (i.e., HR-positive and HER2-negative) and with node-negative status can be spared from adjuvant chemotherapy [5].